Alto Neuroscience (NYSE:ANRO – Get Free Report) released its earnings results on Tuesday. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.07, Yahoo Finance reports.
Alto Neuroscience Price Performance
Shares of NYSE:ANRO traded up $0.53 on Wednesday, reaching $9.51. 81,718 shares of the company traded hands, compared to its average volume of 193,278. The company has a debt-to-equity ratio of 0.05, a quick ratio of 26.02 and a current ratio of 26.02. The firm has a 50 day simple moving average of $11.90. Alto Neuroscience has a fifty-two week low of $7.91 and a fifty-two week high of $24.00.
Insider Transactions at Alto Neuroscience
In other news, insider Adam Savitz acquired 12,069 shares of Alto Neuroscience stock in a transaction on Tuesday, July 9th. The stock was bought at an average cost of $12.60 per share, with a total value of $152,069.40. Following the completion of the purchase, the insider now owns 36,920 shares of the company’s stock, valued at $465,192. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Wall Street Analyst Weigh In
Read Our Latest Research Report on ANRO
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- ETF Screener: Uses and Step-by-Step Guide
- Brinker International’s Price Dip is an Appetizing Entry Point
- The Risks of Owning Bonds
- 3 Stocks That Could Beat the September Blues
- How Investors Can Find the Best Cheap Dividend Stocks
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.